Pfizer Gets Another Chance In Rituxan Patent Challenge
The Patent Trial and Appeal Board agreed Monday to review a Biogen Inc. patent related to the cancer treatment Rituxan, even as the board acknowledged Pfizer Inc. may have used its...To view the full article, register now.
Already a subscriber? Click here to view full article